Compare Amphastar Pharmaceuticals Inc (AMPH) vs JPMorgan Ultra Short Income ETF (JPST) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

JPST, the JPMorgan Ultra-Short Income ETF, trades at $50.45 with no recent price change. The technical outlook is bearish based on moving averages, while oscillators are neutral. The fund focuses on high-quality, short-term bonds, offering a cash alternative with low duration risk. Recent news highlights its role in rising rate environments and strong flows into active ETFs.

The outlook for JPST is stable, appealing to risk-averse investors seeking income and capital preservation amid interest rate uncertainty. Key risks include interest rate sensitivity and credit spread changes. Institutional interest is growing, but the bearish technical signal warrants caution for short-term traders.